trending Market Intelligence /marketintelligence/en/news-insights/trending/krWfni8nUpIwk5cwUQod2w2 content esgSubNav
In This List

XBiotech raises $40M in public offering to fund clinical trials

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


XBiotech raises $40M in public offering to fund clinical trials

Austin, Texas-based XBiotech Inc. completed an underwritten public offering of common shares, raising about $40 million.

The company issued 4,848,485 shares at $8.25 apiece, and granted the underwriter a 30-day option to acquire up to 351,515 additional shares at the same issue price.

XBiotech will primarily use net proceeds to advance phase 2 clinical trials evaluating bermekimab to treat patients with hidradenitis suppurativa, a painful, long-term skin condition that causes infected bumps of skin filled with pus and scarring, and atopic dermatitis, or eczema — a chronic condition that makes skin thick, dry, red and itchy.

The funds will also be used for general corporate and working capital purposes.

Piper Jaffray acted as sole underwriter for the offering.